{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:53Z","timestamp":1740144053379,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["012310"],"award-info":[{"award-number":["012310"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40258-023-00845-1","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T18:02:10Z","timestamp":1701194530000},"page":"243-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-5483","authenticated-orcid":false,"given":"Janet","family":"Bouttell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Goodlad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pam","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin A.","family":"Oien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Seligmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"von Delft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"845_CR1","unstructured":"Haematological Malignancy Research Network (HMRN). Incidence statistics: incidence by diagnosis. https:\/\/hmrn.org\/statistics\/incidence. Accessed 2 Aug 2022."},{"issue":"23","key":"845_CR2","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa055759","volume":"354","author":"SS Dave","year":"2006","unstructured":"Dave SS, Fu K, Wright GW, Lam LT, Kluin age P, Boerma EJ, et al. Molecular diagnosis of Burkitt\u2019s lymphoma. N Engl J Med. 2006;354(23):2431\u201342.","journal-title":"N Engl J Med"},{"issue":"22","key":"845_CR3","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2018-05-851154","volume":"132","author":"A Mottok","year":"2018","unstructured":"Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood Adv. 2018;132(22):2401\u20135.","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"845_CR4","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/blood-2022-159976","volume":"140","author":"AJ Davies","year":"2022","unstructured":"Davies AJ, Stanton L, Caddy J, Barrans S, Wilding S, Saunders GN, et al. Five-year survival results from the Remodl-B trial (ISRCTN 51837425) show improved outcomes in diffuse large B-cell lymphoma molecular subgroups from the addition of bortezomib to R-CHOP chemoimmunotherapy. Blood. 2022;140(Suppl. 1):1770\u20132.","journal-title":"Blood"},{"key":"845_CR5","first-page":"485","volume":"28","author":"W Daneels","year":"2022","unstructured":"Daneels W, Rosskamp M, Macq G, Saadoon EI, De Geyndt A, Offner F, et al. Real-world estimation of first-and second-line treatments for diffuse large B-cell lymphoma using health insurance data: a Belgian population-based study. Front Oncol. 2022;28:485.","journal-title":"Front Oncol"},{"issue":"Suppl. 1","key":"845_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/blood-2022-166228","volume":"140","author":"D Sibon","year":"2022","unstructured":"Sibon D, Gisselbrecht C, Molina TJ, Camus V, Casasnovas O, Recher C, et al. Outcome of patients with primary mediastinal large B-cell lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: a pooled analysis of clinical trials from Lysa. Blood. 2022;140(Suppl. 1):1082\u20134.","journal-title":"Blood"},{"issue":"2","key":"845_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00277-017-3167-7","volume":"97","author":"LE Oosten","year":"2018","unstructured":"Oosten LE, Chamuleau ME, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol. 2018;97(2):255\u201366.","journal-title":"Ann Hematol"},{"issue":"5","key":"845_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178302","volume":"12","author":"JM Yeakley","year":"2017","unstructured":"Yeakley JM, Shepard PJ, Goyena DE, VanSteenhouse HC, McComb JD, Seligmann BE. A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS ONE. 2017;12(5): e0178302.","journal-title":"PLoS ONE"},{"issue":"5","key":"845_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14951","volume":"179","author":"L Giulino-Roth","year":"2017","unstructured":"Giulino-Roth L, O\u2019Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739\u201347.","journal-title":"Br J Haematol"},{"key":"845_CR10","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. Process and methods [PMG36]. 31 January 2022. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation#discounting Accessed 19 Aug 2022."},{"issue":"7","key":"845_CR11","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","volume":"24","author":"T W\u00e4sterlid","year":"2013","unstructured":"W\u00e4sterlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D\u2019Amore F, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24(7):1879\u201386.","journal-title":"Ann Oncol"},{"issue":"2","key":"845_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10198-016-0775-4","volume":"18","author":"HI Wang","year":"2017","unstructured":"Wang HI, Smith A, Aas E, Roman E, Crouch S, Burton C, et al. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ. 2017;18(2):255\u201367.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"845_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649\u201362.","journal-title":"Lancet Oncol"},{"issue":"7","key":"845_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clml.2021.12.018","volume":"22","author":"B Moertl","year":"2022","unstructured":"Moertl B, Dreyling M, Schmidt C, Hoster E, Schoel W, Bergwelt-Baildon MV, et al. Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): a health economic perspective. Clin Lymphoma Myeloma Leuk. 2022;22(7):474\u201382.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"845_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2991\/chi.d.200410.001","volume":"2","author":"B Dholaria","year":"2020","unstructured":"Dholaria B, Vanegas YA, Diehl N, Spaulding AC, Visscher S, Tun HW, et al. Cost analysis of R-CHOP versus dose-adjusted R-EPOCH in treatment of diffuse large B-cell lymphoma with high-risk features. Clin Hematol Int. 2020;2(3):117.","journal-title":"Clin Hematol Int."},{"issue":"4","key":"845_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.15051","volume":"180","author":"NN Shah","year":"2018","unstructured":"Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534\u201344.","journal-title":"Br J Haematol"},{"issue":"26","key":"845_CR17","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","volume":"27","author":"ML De Bruin","year":"2009","unstructured":"De Bruin ML, Sparidans J, van\u2019t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239\u201346.","journal-title":"J Clin Oncol"},{"issue":"8","key":"845_CR18","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1080\/10428190802140873","volume":"49","author":"S Myrehaug","year":"2008","unstructured":"Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486\u201393.","journal-title":"Leuk Lymphoma"},{"issue":"37","key":"845_CR19","first-page":"iii","volume":"8","author":"C Knight","year":"2004","unstructured":"Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin\u2019s lymphoma: systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2004;8(37):iii\u2013x.","journal-title":"Health Technol Assess (Winchester, England)."},{"key":"845_CR20","unstructured":"UK Office for National Statistics. Health consumer price index. Released 20 July 2022. Available from:t CPI INDEX 06 : HEALTH 2015=100 - Office for National Statistics (ons.gov.uk). Accessed 2 Aug 2022."},{"key":"845_CR21","unstructured":"Joint Formulary Committee. 2013.\u00a0British national formulary [64].\u00a0London: BMJ Publishing and the Royal Pharmaceutical Society. Available from: https:\/\/bnf.nice.org.uk\/drugs\/. Accessed 22 Aug 2022."},{"issue":"4","key":"845_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355\u201371.","journal-title":"Pharmacoeconomics"},{"key":"845_CR23","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. 2022;38(1): e13.","DOI":"10.1017\/S0266462321001732"},{"key":"845_CR24","volume-title":"Polatuzumab vedotin in combination for untreated DLBCL: technology appraisal guidance (TA874)","author":"National Institute for Health and Care Excellence","year":"2023","unstructured":"National Institute for Health and Care Excellence. Polatuzumab vedotin in combination for untreated DLBCL: technology appraisal guidance (TA874). National Institute for Health and Care Excellence; London, 2023."},{"issue":"4","key":"845_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363.","journal-title":"N Engl J Med"},{"issue":"42","key":"845_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/EDBK_349307","volume":"20","author":"H Ngu","year":"2022","unstructured":"Ngu H, Takiar R, Phillips T, Okosun J, Sehn LH. Revising the treatment pathways in lymphoma: new standards of care: how do we choose? Am Soc Clin Oncol Educ Book. 2022;20(42):629\u201342.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"845_CR27","unstructured":"REMoDL. Southampton Clinical Trials Unit. https:\/\/www.southampton.ac.uk\/ctu\/trialportfolio\/listoftrials\/remodla.page. Accessed 16 Mar 2023."},{"issue":"7","key":"845_CR28","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","volume":"59","author":"Q Chen","year":"2018","unstructured":"Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700\u20139.","journal-title":"Leuk Lymphoma"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00845-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-023-00845-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00845-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T14:13:58Z","timestamp":1707833638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-023-00845-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1007\/s40258-023-00845-1","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"type":"print","value":"1175-5652"},{"type":"electronic","value":"1179-1896"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"17 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out as part of an Innovate UK Knowledge Transfer Partnership (012321) between the University of Glasgow and BioClavis Limited, which part funded Janet Bouttell, Neil Hawkins, Karin Oien, John Goodlad and Stephan von Delft. Innovate UK had no role in the design, conduct or reporting of the analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bruce Seligmann is a shareholder and employee of BioClavis Limited\u2019s parent company, BioSpyder Inc. Pam McKay declares consulting fees\/honoraria from Roche, Gilead, KITE, Takeda, Janssen, Beigene, BMS\/Celgene and Incyte and conference\/travel support from Gilead, Takeda and Janssen. She also declares lecture fees from Janssen, Beigene and Kitex. Janet Bouttell, Heather Fraser, John R. Goodlad, David Hopkins, Karin A. Oien, Stephan von Delft and Neil Hawkins have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No data were generated as a result of this study. Excel-based models are available on request from the corresponding author. Data used in this study are publicly available and referenced in the text with the exception of the West of Scotland aggressive large B-cell lymphoma cohort data. These cohort data are subject to UK National Health Service data governance.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"No code was generated as a result of this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by JB and DH. The first draft of the manuscript was written by JB and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}